ACCC Addresses Education Needs for Community OncologistsJune 18th 2019
David Spigel, MD, chief scientific officer, Sarah Cannon Research Institute, discussed with <em>Targeted Oncology</em>at the 2019 ASCO Annual Meeting how the Association of Community Cancer Centers (ACCC) is the change agent for helping physicians provide their patients with quality care. <br />
Examining the Current Role of CAR T-Cell Therapy in Acute Myeloid LeukemiaJune 7th 2019
Jae H. Park, MD, discusses the current role and challenges in using CAR T-cell therapy in patients with relapsed or refractory acute myeloid leukemia. The 2 challenges now in this area are target selection and patient selection.
FDA Unveils Project Facilitate to Ease Expanded Access to Experimental Cancer TreatmentsJune 4th 2019
Announced at the 2019 ASCO Annual Meeting, the FDA is rolling out a pilot program that will provide more information and assistance for acquiring expanded access (EA) to investigational therapies for both oncologists and patients. The program is being called Project Facilitate.
Pembrolizumab Demonstrates Antitumor Activity in High TMB Metastatic Breast CancerJune 3rd 2019
Findings from a cohort of the phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study revealed that heavily pretreated patients with metastatic breast cancer and high mutational burden benefited from pembrolizumab monotherapy.
Translational Immunotherapy Research Informs Ongoing Efforts to Improve Treatment OutcomesMay 20th 2019
Robert L. Ferris, MD, PhD, co-physician editor-in-chief, discusses the excitement of immunotherapy at the 2019 AACR Annual Meeting and how this research can inform resarch efforts moving forward.
Immunotherapy Potential in Breast Cancer Draws ExcitementMay 13th 2019
Findings from ongoing immunotherapy studies are expected to change the treatment paradigm in breast cancer as these agents become available to larger subsets of patients, according to Hope S. Rugo, MD, and Elizabeth A. Mittendorf, MD, PhD, who presented data at the 36th Annual Miami Breast Cancer Conference® hosted by Physicians’ Education Resource®, LLC.
FDA Approves Pembrolizumab With Axitinib for Frontline Treatment of RCCApril 22nd 2019
Pembrolizumab (Keytruda) has received approval from the FDA in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma, based on phase III findings from the KEYNOTE-426 trial.
Coverage Concerns Temper Enthusiasm Surrounding CAR T-Cell TreatmentApril 12th 2019
A discussion between regulators and special interest groups has cooled some of the excitement generated by the emergence of chimeric antigen receptor T-cell therapy for treating hematologic cancers.
Immune Checkpoint Inhibitors Approach Frontline Setting in Head and Neck Squamous Cell CancerApril 5th 2019
Immune checkpoint inhibitors as monotherapy and in combinations regimens are producing promising efficacy data in metastatic head and neck cancers, depite struggles in finding the right treatment settings and patient population subsets.
Challenges Persist With CAR T-Cell Therapy in Pancreatic CancerApril 2nd 2019
The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.
Mesothelin-Targeted CAR T-Cell Therapy Shows Early Efficacy in Advanced Solid CancersApril 1st 2019
In findings presented during the 2019 AACR Annual Meeting, safety and efficacy was seen with CAR T cells targeting mesothelin-expressing tumors in a preliminary clinical evaluation in patients with malignant pleural disease.
Evolving Standards of Care in Melanoma and Non-Small Cell Lung CancerMarch 14th 2019
Robert L. Ferris, MD, PhD, Co-Physician Editor in Chief, <em>Targeted Therapies in Oncology</em>,<em> </em>discusses<em> </em>the<em> </em>evolving<em> </em>role of immunotherapy in melanoma and non–small cell lung cancer, where by it is now the dominant therapeutic approach in these diseases in progressively earlier lines of therapy.
Greater Communication and Care Coordination Needed to Stimulate Growth of Immunotherapy, Says ACCCMarch 14th 2019
Less than 20% of healthcare providers feel very comfortable administering and prescribing appropriate and timely treatment to manage adverse events associated with immuno-oncology therapy, according to an independent needs assessment conducted by the ACCC IO Institute.
Medicare Makes Move Toward CAR T-Cell Therapy CoverageFebruary 19th 2019
To date, there is no national Medicare policy in place to provide coverage for CAR T-cell therapies, which have been proven to be a successful treatment for certain patients with relapsed/refractory cancers. Now, the Centers for Medicare & Medicaid Services has proposed to cover CAR T-cell therapies approved by the FDA under “Coverage with Evidence Development."
The Introduction of Immunotherapy to the Treatment of Head and Neck CancersFebruary 5th 2019
Ezra Cohen, MD, discusses the advancing field of immunotherapy in the treatment landscape for patients with head and neck cancers. Prior to the use of PD-1/PD-L1 blockades, which have been the most tested immunotherapy in this setting, there were little treatment options.